Metabolic Research

Three Hypotheses Currently in Play

The most cited explanation is desensitization: chronic GIPR agonism may drive receptor internalization to a degree that functionally resembles antagonism. Under this model, both approaches converge on the same downstream state through different routes. A second hypothesis attributes most of tirzepatide's weight loss effect to GLP-1R bias, with the GIPR component playing a supporting role. A third, gaining traction in 2025, proposes that GIPR activity in adipose tissue versus the central nervous system has opposite metabolic effects — peripheral antagonism removes lipid-storage signals while central agonism enhances satiety, and clinical compounds may achieve both endpoints through different mechanisms. None of the three is settled.

Catalog Compound Classes and Their Research Context

The compounds in this catalog map onto distinct research questions rather than a single therapeutic target. GLP-1R agonists (Semaglutide analogs, Liraglutide analogs, Retatrutide-class triagonists) are studied for receptor pharmacology, biased signaling, and combination effects. Amylin analogs (Cagrilintide) target a separate satiety pathway through the calcitonin receptor family and are typically studied in dual-pathway combinations with GLP-1R agonists. AMPK activators (AICAR, 5-Amino-1MQ) sit on an older pre-incretin framework — cellular energy sensing, fatty acid oxidation, mitochondrial biogenesis. They predate the GLP-1 era by roughly two decades and remain workhorses in basic metabolic research.

Mitochondrial peptides deserve their own note because the terminology is often used loosely. MOTS-c is mitochondrial-derived in the literal sense — encoded within the 12S rRNA of mitochondrial DNA, discovered by Pinchas Cohen's lab in 2015. SS-31 (Elamipretide) is synthetic and mitochondrial-targeting through cardiolipin binding on the inner mitochondrial membrane. Both are studied for energy homeostasis, but their origins and mechanisms differ enough that researchers usually treat them as separate compound classes.

Research Models Commonly Used

Preclinical metabolic peptide work clusters around a small set of standard models. Diet-induced obesity (DIO) in C57BL/6 mice on 60% high-fat diet for 12–16 weeks remains the default for weight-loss endpoint studies. db/db mice (leptin receptor mutant) and ob/ob mice (leptin-deficient) cover the genetic side of obesity research. For incretin-specific work, GIPR knockout and GLP-1R knockout lines have produced much of the field's mechanistic foundation — and, notably, both knockouts show similar phenotypes when fed high-fat diets, which is itself one of the data points feeding the current paradox. Human translational work uses hyperinsulinemic-euglycemic clamps, oral glucose tolerance tests, and increasingly, ambulatory continuous glucose monitoring.

Frequently Asked Questions

Reference Points for Further Reading

The 2025 Diabetes point-counterpoint on GIP receptor pharmacology (volume 74, issue 8) is the most current overview of the active controversy and is open-access through the American Diabetes Association journals. For the broader incretin field, the 2024 reviews by Drucker (Cell Metabolism) and by Müller and Tschöp (Nature Reviews Endocrinology) remain standard reference points. For mitochondrial peptide biology, the Cohen group at USC has published the foundational MOTS-c literature; Szeto's work at Cornell covers the SS-31 mechanism in detail.

All compounds in this catalog are intended for in vitro and preclinical research use only. None are approved by the FDA or any other regulatory authority for therapeutic use in humans. The clinical and trial data referenced on this page describe research conducted with FDA-approved or investigational pharmaceutical products and are provided as scientific context, not as claims for the research compounds offered here.